Low-level fluoroquinolone resistance among Campylobacter jejuni isolates in Australia

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Leanne UnicombAustralian Campylobacter Subtyping Study Group

Abstract

Ciprofloxacin-resistant Campylobacter jejuni isolates obtained from infected patients in Australia have not been detected in studies of isolates from specific geographic areas. The Australian government has prohibited the use of fluoroquinolone in food-producing animals. To assess the impact of this policy, we have examined the antimicrobial susceptibility of isolates from 5 Australian states. We conducted a period-prevalence survey of the susceptibility of C. jejuni isolates to 10 antimicrobial agents. C. jejuni isolates obtained from 585 patients from 5 Australian states (Queensland, South Australia, Tasmania, Victoria, and Western Australia) were identified by means of notifiable disease databases and were systematically selected from September 2001 to August 2002. Among locally acquired infections, only 2% of isolates (range, 0%-8% in different states) were resistant to ciprofloxacin. The locally acquired isolates also exhibited resistance to sulfisoxazole (55%), ampicillin (46%), roxithromycin (38%), tetracycline (7%), nalidixic acid (6%), chloramphenicol (3%), erythromycin (3%), gentamicin (2%), and kanamycin (0.2%). Treatment with antimicrobial agents in the 4 weeks before onset was not associated with ciprofloxacin resi...Continue Reading

References

Apr 1, 1997·International Journal of Systematic Bacteriology·J P Euzéby
May 1, 1997·Pathology·M B Huysmans, J D Turnidge
May 20, 1999·The New England Journal of Medicine·K E SmithM T Osterholm
Dec 10, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E TalsmaM J Sprenger
Dec 4, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kurt B Nolte
May 4, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Karin Travers, Michael Barza
Oct 3, 2002·The Journal of Antimicrobial Chemotherapy·UNKNOWN Campylobacter Sentinel Surveillance Scheme Collaborators
Dec 25, 2002·Emerging Infectious Diseases·Irving NachamkinMing Li
Sep 30, 2003·Scandinavian Journal of Infectious Diseases·Anders OsterlundGunnar Kahlmeter
Jan 14, 2004·Emerging Infectious Diseases·Leanne UnicombPeter Collignon
Jun 23, 2004·Emerging Infectious Diseases·Amita GuptaUNKNOWN NARMS Working Group
Aug 21, 2004·The Journal of Infectious Diseases·Jennifer M NelsonFrederick J Angulo
Aug 28, 2004·Journal of Veterinary Medicine. B, Infectious Diseases and Veterinary Public Health·W S HartM D Barton
Aug 17, 2005·Emerging Infectious Diseases·Gillian HallUNKNOWN OzFoodNet Working Group

❮ Previous
Next ❯

Citations

Nov 17, 2006·Nature Reviews. Microbiology·Randall S SingerGeorge Maldonado
Jun 19, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Martyn D KirkJoy Gregory
Dec 24, 2009·Biosecurity and Bioterrorism : Biodefense Strategy, Practice, and Science·Kunal J Rambhia, Gigi Kwik Gronvall
Jan 11, 2007·Antimicrobial Agents and Chemotherapy·Sebastian WardakRafal Gierczynski
Mar 20, 2008·Annual Review of Public Health·Ellen K SilbergeldLance B Price
Aug 31, 2012·Emerging Infectious Diseases·Allen C ChengThomas Gottlieb
Mar 29, 2014·International Journal of Food Microbiology·Secil AbayNurhan Ertas
Mar 13, 2009·Wiener klinische Wochenschrift·Gebhard Feierl, Sandra Jelovcan
Jan 14, 2009·The Science of the Total Environment·A J WatkinsonS D Costanzo
Apr 11, 2007·International Journal of Antimicrobial Agents·Trudy M WassenaarAnno de Jong
Sep 17, 2008·Risk Analysis : an Official Publication of the Society for Risk Analysis·Louis Anthony Tony Cox, Douglas A Popken
Jan 3, 2013·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Vincent P RichardsMichael J Stanhope
Feb 15, 2013·Virulence·Nicole M Iovine
Nov 23, 2007·FEMS Microbiology Letters·David A Alfredson, Victoria Korolik
Jan 22, 2009·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F B L FeodoroffH I K Rautelin
Nov 23, 2006·The Journal of Antimicrobial Chemotherapy·Teresa QuinnSéamus Fanning
Nov 7, 2019·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Mehmet IlktacLisa K Williams
Apr 30, 2020·Animals : an Open Access Journal From MDPI·Beata WysokJoanna Szteyn
Sep 9, 2020·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Rhiannon L WallaceMartyn D Kirk
Jun 27, 2019·International Journal of Environmental Research and Public Health·Martina O ChukwuJohn Barr Dewar
Jun 12, 2010·Journal of Food Protection·James L Smith, Pina M Fratamico

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Campylobacteriosis

Campylobacteriosis is caused by the bacteria Campylobacter jejuni and is a common cause of gastroenteritis in humans. Discover the latest research on Campylobacteriosis here.

Campylobacteriosis (ASM)

Campylobacteriosis is caused by the bacteria Campylobacter jejuni and is a common cause of gastroenteritis in humans. Discover the latest research on Campylobacteriosis here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.